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O steoprotegerin (OPG), a secretedglycoprotein andmember of the tu-mor necrosis factor (TNF) receptor
superfamily, is a soluble receptor activa-
tor of nuclear factor-B (RANK) ligand
(RANKL) and TNF-related apoptosis-
inducing ligand (1). OPG works as a de-
coy receptor preventing RANK/RANKL-
induced osteoclast differentiation and
activation (2). Moreover, the RANK/
RANKL system has potential cardiovascu-
lar effects; the system induces vascular
cell adhesionmolecule (VCAM)-1 synthe-
sis, prolongs endothelial cell survival, and
promotes angiogenesis (3,4). Furthermore,
OPG may be involved in cardiovascular
disease (CVD). An epidemiological study
identified OPG as an independent risk
factor for CVD (5) and OPG is present in
high concentrations in the arterial wall
(6,7). Of note, diabetic patients are char-
acterized by elevated OPG (3), which is
associated with subclinical atherosclero-
sis in both type 1 (8) and type 2 (9) dia-
betes. Conversely, OPG may inhibit
calcification inmice (10). Hence, it is pos-
sible that vascular calcification increases
OPG, which then, in turn, is involved in
calcification inhibition (4).
Development of atherosclerosis in-
volves expression of adhesion molecules
(e.g., VCAM-1 and intercellular adhesion
molecule [ICAM]), allowing cellular at-
tachment and migration of monocytes
and macrophages into the vascular wall
(11). Recent in vitro studies suggest that
statins may suppress both OPG (12) and
adhesion molecule (13) production.
Statin treatment reduces cardiovascu-
lar disease in type 2 diabetes (14). More-
over, additional so-called pleiotropic
effects have also been proposed (15).
Since both OPG and adhesion molecules
are associated with CVD and potentially
modifiable by statins, we examined the
effect of simvastatin on OPG and adhe-
sion molecules in type 2 diabetic patients
at increased risk for CVDdue to persistent
microalbuminuria.
RESEARCH DESIGN AND
METHODS— Informed consent was
obtained from all participants, and the
study received ethics committee ap-
proval. Eighteen type 2 diabetic patients
were randomly recruited from the outpa-
tient clinic (16). Inclusion criteria were
microalbuminuria (overnight urinary al-
bumin excretion 15–200 g/min),
plasma cholesterol 5.5 mmol/l, plasma
triglyceride 4.5 mmol/l, A1C 10%,
serum C-peptide 0.49 nmol/l, and
blood pressure 160/95 mmHg.
The study design has previously been
described (16). In brief, in a randomized,
double-blind design, patients were allo-
cated to treatment with 10 mg/day simva-
statin or the placebo group for 18 weeks.
If plasma cholesterol was5.2 mmol/l at
6 weeks, the dose was doubled. Blood
samples for OPG, VCAM-1, and ICAM
were collected after an overnight fast at
baseline and week 18. Sampling for OPG
was insufficient for one patient in the pla-
cebo group. Sample size was based on
previously decided main outcome mea-
surements of renal function (16). Since no
interventional studies describing changes
in OPG could be identified from the liter-
ature, we were unable to perform a valid
sample size calculation. We therefore in-
cluded all patients from that study.
OPGwasmeasured by a sandwich en-
zyme-linked immunosorbent assay (R&D
Systems, Minneapolis, MN) using a
mouse anti-human OPG as capture anti-
body and a biotinylated goat anti-human
OPG for detection. Recombinant human
OPG was used for calibration. Samples
were diluted and measured in duplicate
(8). Serum ICAM and VCAM-1weremea-
sured bymonoclonal antibody–based en-
zyme-linked immunosorbent assays as
described by the manufacturer (catalog
nos. BBE1B, BBE3, and DY809, respec-
tively; R&D Systems).
Data are presented as means  SEM.
Between-group differences were analyzed
using Student’s t test or the Mann-
Whitney two-sample test. Changes were
also evaluated as the 18 weeks–to–
baseline ratio. Correlations were evalu-
ated by Pearson’s r.
RESULTS— The treatment groups
were similar with respect to age, sex, dia-
betes duration, BMI, A1C, and serum C-
peptide. The average simvastatin dose
was 12.5 mg/day. Cholesterol was signif-
icantly reduced by simvastatin. A1C re-
mained unchanged.
OPG levels were comparable at base-
line (1,660 161 vs. 1,961 131 pg/ml
for the placebo vs. simvastatin groups, re-
spectively) and after 18 weeks (1,684 
154 vs. 1,816  95 pg/ml), and within-
group changes were not statistically sig-
nificant. However, simvastatin treatment
was associated with a significant reduc-
tion of baseline–to–18 weeks OPG ratio
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compared with that in the placebo group
(Fig. 1).
No significant differences were ob-
served at baseline in VCAM-1 (755  64
vs. 690  51 ng/ml for the placebo vs.
simvastatin groups, respectively) or
ICAM (307  83 vs. 336  33 ng/ml).
Moreover, the 18 weeks–to–baseline ra-
tios were comparable between groups.
There was no significant correlation
between the change in cholesterol and
OPG ratio in the simvastatin group or be-
tween total cholesterol and OPG,
VCAM-1, or ICAM at baseline in the com-
bined group. OPG and A1C tended to
correlate at baseline (r2 0.46, P 0.06)
and week 18 (r2  0.48, P  0.07).
Plasma insulin (picomoles per liter) cor-
related significantly with OPG at week 18
(r2  0.56, P  0.05).
CONCLUSIONS— In this study,
low-dose simvastatin treatment for 18
weeks reduced OPG levels in type 2 dia-
betic patients with microalbuminuria and
mild hypercholesterolemia. To our
knowledge, this has not previously been
demonstrated in humans in vivo.
The cellularmechanismwhereby stat-
ins affect OPG is unclear. Statins modu-
late inflammatory mediators on OPG
secretion. Thus, simvastatin reduces
TNF-–induced OPG levels in vitro (12)
and directly inhibits the nuclear factor-B
system (12,17). Moreover, OPG mRNA
and RANKL mRNA were increased in
mouse bone-cell cultures incubated with
simvastatin for 7–16 days (18). These re-
sults seem contrary to ours, since we
found decreased OPG levels. However,
the different study design (in vitro vs. in
vivo) and treatment duration (7 and 16
days vs. 18 weeks) may partly explain the
differences. Moreover, since OPG is in-
volved in calcification inhibition, at least
in mice (10), our findings may reflect a
simvastatin-mediated calcification reduc-
tion, which, in turn, might downregulate
OPG. In type 2 diabetes, microalbumin-
uria is not known to be related to altered
bone mineral metabolism.
Contrary to previous reports (19), we
found no change in VCAM-1 or ICAM.
These adhesion molecules are induced
by inflammatory cytokines (i.e., TNF-
and interleukin-1), oxidative stress, and
oxidized LDL (20). In theory, the anti-
inflammatory and LDL-lowering effects
of simvastatin should, therefore, exert
an inhibitory effect on adhesion mole-
cule expression (17,19). To our knowl-
edge, this has never been shown in
human in vivo studies. Mulder et al.
(21) recently reported that switching to
more aggressive lipid lowering in patients
already on statin treatment may not have
further effects on adhesion molecule ex-
pression. We included statin-na¨ive pa-
tients in the present study. Although the
inclusion criteria do not adhere to today’s
standards of clinical care, we think that
the interpretations of the results are not
hampered in amajor way. Our inability to
show changes in adhesion molecules may
be due to the relatively low statin dose,
the study duration, or the number of pa-
tients included.
In summary, 18 weeks of low-dose
simvastatin treatment reduced circulat-
ing OPG levels in type 2 diabetic pa-
tients with microalbuminuria but had
no effect on VCAM-1 or ICAM. The re-
duction of OPG was independent of
cholesterol and suggests a pleiotropic
effect of simvastatin per se. The OPG-
lowering effect of simvastatin may sig-
nal diminished vascular calcification.
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